Use of Non-invasive Ventilation in Motor Neuron Disease – A Retrospective Cohort Analysis

Laura J Walsh (✉ lauraj.walsh@hse.ie)  
University College Cork National University of Ireland  https://orcid.org/0000-0002-7813-7360

Kevin F Deasy  
Cork University Hospital

Fernando Gomez  
Cork University Hospital

Elizabeth O’Sullivan  
Cork University Hospital

Joseph Eustace  
HRB: Health Research Board

Aisling M Ryan  
Cork University Hospital

Desmond M Murphy  
Cork University Hospital

Research

**Keywords:** motor neuron disease, respiratory failure, non-invasive ventilation, pulmonary function tests

**DOI:** https://doi.org/10.21203/rs.3.rs-657662/v1

**License:** ☒️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background Motor neuron disease (MND) is a neurodegenerative disorder which leads to progressive muscle weakness including respiratory muscle function decline. The introduction of non-invasive ventilation (NIV) has been shown to improve quality of life, survival and slow the rate of pulmonary function decline. Better compliance with the machine (using it for greater than 4 hours per day) has been shown to have the greatest long-term benefit.

Methods A retrospective chart analysis of patients who attended the MND clinic from 2014-2019 at a tertiary-referral, academic, teaching hospital was carried out to evaluate if NIV and greater compliance with NIV was associated with improved survival. Information regarding NIV use, compliance, pulmonary function tests (PFTs) and basic patient demographics was collected. In total 111 patients were included in the study.

Results The mean age at diagnosis was 63.8 years and 61.3% were males. 66.7% of our patient cohort used NIV and of this 44.1% were compliant. There was a statistically significant longer survival in those who used NIV ($P=0.002$) and in those who used NIV optimally ($P=0.02$) when both groups were compared to those who did not use NIV. In the bulbar MND group those who were compliant with NIV survived longer than who those who did not use NIV ($P=0.001$). Patients with bulbar onset MND had worse SNIP and peak cough flow values at diagnosis.

Conclusion We found a significantly longer survival with the use of NIV, the use of NIV optimally and with use of NIV in those with bulbar onset MND compared to those who did not use NIV.

Background

Motor neuron disease (MND) is a neurodegenerative disorder which leads to progressive muscle weakness and respiratory compromise due to loss of motor neurons in the brain, brainstem, and spinal cord [1–3]. The typical age of onset is in the mid-late 50’s and there is a slight male predominance with males twice as likely to be affected. Survival is approximately 3–5 years after diagnosis with the most common cause of death being due to respiratory failure [1–4]. The estimated incidence of MND in the United Kingdom is 2.76 per 100,000 [5]. Currently, there is no cure for MND but there have been some advances which have improved survival and quality of life for those with the condition. The only approved drug for MND is riluzole which works by slowing disease progression and has been demonstrated to prolong survival by 2–3 months [6]. The phenotypical subtypes of MND are based on the affected area of disease onset and include limb and bulbar onset.

Regardless of the site of onset however, respiratory muscle dysfunction is a key clinical aspect of MND and declines as the disease progresses. Many patients already show evidence of pulmonary function impairment at the time of diagnosis [7]. Symptoms due to respiratory muscle involvement include dyspnoea and nocturnal hypoventilation which can lead to morning headaches, orthopnoea, poor concentration, unrefreshing sleep, fatigue, and daytime somnolence with a resulting negative impact on
the patients’ quality of life [7–10]. The introduction of NIV may help alleviate these symptoms and has been shown to improve quality of life, survival and slow the rate of pulmonary functional decline in numerous studies [6, 10, 11–17]. Non-invasive positive pressure ventilation is the most commonly used form of NIV in MND as it most closely replicates physiological conditions, reduces symptoms, improves sleep quality and gas exchange [18–20].

There is a paucity of clear guidance outlining the optimal time-point in the course of the disease, at which to initiate NIV, but small studies suggest that the earlier NIV is initiated the better the outcome for the patient, in terms of survival and quality of life [6, 11, 21–23]. Other important aspects to consider are tolerance and compliance with NIV once it has been established, with studies showing that the use of NIV for more than 4 hours a day has the greatest potential for long-term benefit [6, 7, 11, 12, 17]. It has previously been shown that bulbar onset MND can lead to poorer compliance with NIV and therefore this cohort of patients do not get the same benefit in terms of survival and quality of life improvements [7].

In terms of markers of pulmonary function decline, sniff nasal inspiratory pressure (SNIP) has been found to correlate well with transdiaphragmatic pressures and has demonstrated an ability to predict respiratory muscle function as it linearly declines with disease progression [24–28]. SNIP can be performed more easily than spirometry, in patients with advanced disease and is a reliable predictor of mortality and is a better indicator of early respiratory muscle dysfunction than forced vital capacity (FVC) [24–28]. Furthermore, its measurement does not require a tight mouth seal which may not be possible for many patients with bulbar onset MND [25].

In this study, we aimed to review data on MND patients who attended a multidisciplinary MND clinic between September 2014 and September 2019 at our institution; a tertiary-referral, academic, teaching hospital to determine whether the use of NIV had any survival advantage in this patient cohort.

Methods

A retrospective chart analysis of all patients who attended a multidisciplinary MND clinic at our institution from September 2014- September 2019 was performed. All charts of those attending this clinic were reviewed. Patients who did not have a definite or probable diagnosis of MND were excluded. Patients that had not yet been set up on NIV at the time of study commencement were also excluded, as were those who died or failed to attend clinic after their diagnosis to discuss the use of NIV. This resulted in the inclusion of N = 111 patients in this study.

Data collected from the patient’s chart included basic patient demographics, the use of NIV, age at diagnosis and type of MND i.e. bulbar or limb onset MND. Data on compliance with NIV was obtained both from compliance records in the patient’s charts and through the ResMed online system who provided the majority of NIV machines to this cohort of patients. Optimal use of NIV was defined as use of the machine for greater than 4 hours per day and for greater than 70% of the days used. Increased patient reliance on NIV with disease progression is typical in MND. Therefore, it was felt that patients who demonstrated initial compliance with the machine would probably demonstrate good levels of
compliance throughout the clinical course of their disease. Survival (in months) was defined as the time from MND diagnosis to patient death, or if patient was still alive then time from diagnosis to their last clinic attendance until a cut-off point of January 2020 when data collection was completed.

Pulmonary Function Test (PFT) results were also collected from the patient records. We aimed to collect FVC, peak cough flow (PCF) and SNIP results both at diagnosis and at time of commencing NIV. The use of riluzole and the use of a cough assist machine were also recorded as was the location of NIV set up.

At our institute, the MND clinic is attended by both a Neurologist and Respiratory Physician. In addition, other members of the attending team include a physiotherapist who regularly carries out spirometry on each patient, a speech and language therapist, and a dietician. All patients attending the clinic are offered NIV as soon as possible after diagnosis is confirmed either as an inpatient or at home. The preferred method at our institution is inpatient set up within the hospital. During this time, the patient is assessed by the multidisciplinary team, PFTs are performed and NIV is set up and trialled. The machine utilised for in-patient set-up is the same machine the patient is discharged home with for their ongoing use.

Statistical analysis

Descriptive statistics were used to analyse patient characteristics. Normally distributed continuous data was described using means and standard deviations (SD). The categorical variables were reported in percentages of total subjects. Patient characteristics were compared using independent sample t tests for continuous variables and Pearson's $\chi^2$ test for categorical variables. Kaplan-Meier method was used to plot survival distributions. We performed statistical analyses for the full study cohort (all phenotypes), followed by a subgroup analysis with patients grouped according to their clinical phenotype. A p value of $\leq 0.05$ was considered significant. The data was analysed using SPSS Statistics version 24 (IBM Corp. Armonk, NY, USA).

Ethical approval for this study was granted by the Cork Research Ethics Committee, Cork Ireland.

**Results**

Demographics

Patient characteristics are shown in Table 1. There were $n = 111$ patients included in the study, of which $n = 47$ (42.3%) had bulbar onset MND and $n = 64$ (57.7%) had limb onset MND. The average age at diagnosis was 63.8 years with a statistically significant younger age at diagnosis in the limb onset MND cohort (bulbar 66.8 years v limb 61.7 years, $P = 0.02$). 61.3% of those included in the study were males. Riluzole was used by 85.6% of the total patient cohort. Only 27.8% of patients had a percutaneous endoscopic gastrostomy (PEG) tube placed with more than half of the bulbar MND cohort requiring PEG placement. 71.6% of the cohort used a cough assist.

Non-Invasive Ventilation

In the total population, 80.2% of patients trialled NIV while 66.7% maintained use. 73.7% of the bulbar MND group continued using NIV and 61.8% in the limb onset MND group continued with NIV. Optimal use of NIV, defined as use for more than 70% of days and for greater than 4 hours per day was observed in 44.1% of patients who continued using NIV. Those with bulbar onset MND
were more compliant and had better usage when compared to those with limb onset MND (55.3% v 36.4%, \( P = 0.07 \)).

Pulmonary Function tests PFTs at diagnosis were not available for all patients with only 78 patients having an FVC value recorded around the time of diagnosis. The mean FVC at diagnosis for the whole group was 78.7% predicted. Those with bulbar onset MND had an average FVC of 73.13% predicted while the FVC for the limb group at diagnosis at 82.64% predicted. However, there was a statistically significant difference between mean SNIP values at diagnosis for those with bulbar onset MND (35.85% predicted) compared with those with limb onset MND (52.98% predicted, \( P = 0.01 \)). There was also a statistically significant difference in the peak cough flow (PCF) between patients with bulbar onset MND
Table 1

Patient demographics. Column one shows cumulative data from all patients included in the study (n = 111, unless otherwise stated) while columns two and three show the breakdown as per bulbar onset MND and limb onset MND, respectively. Survival was calculated in months from time of diagnosis.

|                                      | All (n = 111) | Bulbar (n = 47) | Limb (n = 64) | p-value |
|--------------------------------------|--------------|-----------------|---------------|---------|
| Age at Onset                         | 63.83        | 66.8            | 61.7          | 0.02    |
| SD                                   | 11.4         | 7.8             | 13.1          |         |
| Gender (Male)                        | 61.3%        | 57.4            | 64.1          | 0.48    |
| NIV Trialled                         | 80.2%        | 76.6%           | 82.8%         | 0.42    |
| NIV Maintained                       | 66.7%        | 73.7%           | 61.8%         |         |
| Optimal NIV Usage (of those who maintained use) | 44.1%        | 55.3%           | 36.4%         | 0.07    |
| NIV Settings                         |              |                 |               |         |
| IPAP                                 | 10.7         | 10.3            | 11            | 0.06    |
| EPAP                                 | 4.3          | 4.2             | 4.4           | 0.23    |
| Riluzole                             | 85.6%        | 85.1%           | 85.9%         | 0.90    |
| PEG n = 108                          | 27.8%        | 56.5%           | 6.5%          | 0.001   |
| Cough Assist n = 95                  | 71.6%        | 76.2%           | 67.9%         | 0.38    |
| FVC n = 78 (%predicted)              |              |                 |               |         |
| Mean at Dx                           | 78.74%       | 73.13%          | 82.64%        | 0.13    |
| SD                                   | 27.47%       | 28.07%          | 26.66%        |         |
| SNIP n = 106 (%predicted)            |              |                 |               |         |
| Mean at Dx                           | 45.55%       | 35.85%          | 52.98%        | 0.01    |
| SD                                   | 27.14%       | 25.17%          | 26.42%        |         |
| SNIP Decline (slope) n = 85          |              |                 |               |         |
| Mean                                 | -1.74        | -1.73           | 1.75          | 0.98    |
| SD                                   | 2.36         | 2.33            | 2.41          |         |
| Peak Cough n = 107(L/min)            |              |                 |               |         |
| Mean at Dx                           | 239.94       | 210.21          | 263.23        | 0.03    |
| SD                                   | 125.42       | 109.22          | 133.07        |         |
and limb onset MND (210.21 L/min versus 263.2 L/min, \( P = 0.03 \)). SNIP and PCF values within 6 months of death were available for 44 patients and showed that the average SNIP at diagnosis was 37.36% predicted while in the last 6 months before death the average was 21.97% predicted, \( P = 0.001 \). Similarly, the average PCF at diagnosis was 215 L/min while within 6 months of death it was 133.5 L/min, \( P = 0.005 \). Figure 2 shows the gradual decline in SNIP and PCF in the year prior to death (\( n = 61 \)).

### Table 2

Comparison of data for those who were given NIV regardless if they achieved compliance or not versus those who never used NIV. Those who used NIV had a statistically significant longer survival than those who never used NIV, \( p = 0.02 \).

|                       | All (n = 111) | NIV (ITT) (n = 93) | No NIV (n = 18) | p-value |
|-----------------------|--------------|--------------------|-----------------|---------|
| **Age at Onset**      | 63.83        | 64.21              | 62.27           | 0.478   |
| **SD**                | 11.4         | 10.5               | 14.8            |         |
| **Gender (Male)**     | 61.3%        | 61.8%              | 59.1%           | 0.815   |
| **Bulbar Onset**      | 42.3%        | 40.4%              | 50%             | 0.417   |
| **Survival (months)** |              |                    |                 |         |
| **Median (95% CI)**   | 26 (19–33)   | 28 (22–34)         | 12 (7–17)       | 0.002   |

Survival

Overall survival was 26 months from the date of MND diagnosis. Survival was significantly longer in the limb MND group regardless as to whether patients used NIV or attained compliance when compared with those with bulbar MND (33 months v 17 months, \( P = 0.01 \)), Fig. 1A. Table 2 compares survival in those who were treated with NIV regardless of compliance and usage i.e. with intention to treat versus those who never used NIV. Those who were treated with NIV had a statistically significant longer survival compared to those who never used NIV (28 months v 12 months, \( P = 0.002 \)). Similarly, as illustrated in Table 3 and Fig. 1B, when survival in those who used NIV optimally i.e. were compliant and
used for more than 4 hours per day was compared to those who never used NIV, those who optimally used NIV survived longer (26 months v 12 months, $P = 0.021$). Figure 1C demonstrates that when this cohort is broken down into phenotypic subtypes, those with bulbar MND survived longer with optimal NIV use compared with those with bulbar MND who did not use NIV ($P = 0.001$). This impact was not seen in patients with limb onset MND, Fig. 1D.

NIV set-up Although the aim of our institute is to admit MND patients and set up NIV as an inpatient in a controlled environment, this is not always possible. Table 4 gives a breakdown of NIV set up location and associated compliance. Data was available for n = 90 patients and showed that 70% (n = 63) were commenced on NIV in an inpatient setting with the remaining opting for a home set up. 74.1% of those who had a home set up were compliant while 63.5% who had an inpatient set up were compliant with NIV.

**Table 3:** Those who used NIV optimally, as defined by use for more than 4 hours per day and for more than 70% of the time were compared with those who did not use NIV. Particular attention should be paid to the survival data when these two groups are compared.

|                          | “Optimal NIV” | No NIV (n=18) | p-value |
|--------------------------|---------------|---------------|---------|
|                          | (n=41)        |               |         |
| Age at Onset             | 65.76         | 61.11         | 0.160   |
| $SD$                     | 9.1           | 15.8          |         |
| Gender (Male)            | 68.3%         | 66.7%         | 0.902   |
| Bulbar Onset             | 51.2%         | 50            | 0.931   |
| **Survival (months)**    |               |               |         |
| Median (95% CI)          | 26 (19-33)    | 12 (7-17)     | 0.021   |

**Table 4:** Location of NIV set up i.e. home versus in hospital set up and associated compliance.

|                          | Inpatient | Home set up |
|--------------------------|-----------|-------------|
| Set up                   | N         | N           |
|                          | 63        | 27          |
| Compliant (%)            | 40 (63.5%)| 20 (74.1%)  |
| Non- compliant           | 23 (36.5%)| 7 (25.9%)   |

**Discussion**
This study of MND patients attending a multidisciplinary clinic found that 66.7% of the patient cohort were treated with NIV and of this, 44.1% used NIV optimally. It has been shown in previous studies that better compliance and longer use of the machine is associated with prolonged survival with Piepers et al 2006 and Bourke et al 2003, both showing that survival improved with better compliance compared to those who did not tolerate or did not use NIV, while Kleopa et al 1999 showed that those who used NIV for 4 or more hours per day survived longer than those who did not use NIV [7, 12, 17]. When those with bulbar onset MND were compared with those with limb onset MND, the bulbar MND group had better compliance and better machine usage. This may be due to poorer respiratory function and a greater need for NIV amongst the bulbar group. Review of the literature shows varying results regarding compliance and tolerance of NIV in those with bulbar MND with some finding that those with bulbar onset MND had a decreased benefit due to intolerance and that NIV was difficult to establish in bulbar MND [7, 16]. In contrast, other studies have found that the area of MND onset did not affect tolerance [12].

In our population cohort, those with limb onset MND survived significantly longer than those with bulbar onset MND (33 months v 17 months). This is not unexpected as bulbar onset MND is known to have a worse prognosis [29]. There was a statistically significant longer survival in those who used NIV compared to those who never used NIV (28 months v 12 months). This is in keeping with multiple studies including the only randomised control trial on this topic by Bourke et al 2006 [7, 12-17, 21, 30]. Furthermore, there was significantly longer survival in those who used NIV optimally compared with those who never used NIV. This survival advantage has been previously demonstrated in several studies [7, 15, 31, 32]. Of additional interest, those who used NIV regardless of compliance and pattern of onset survived 2 months longer on average than those who optimally used NIV. This may be as a consequence of having smaller patient numbers in the optimal use NIV group (n=41 v n=93) and that this group had a slightly higher proportion of bulbar onset MND patients (51% v 40.4%). When this data was examined for each phenotypic subgroup, it was found that optimal use of NIV in the bulbar onset MND group compared with those that did not use NIV had a statistically significant longer survival (23 months v 8 months). This same survival benefit was not seen for the limb onset MND group. This finding would be in keeping with the results of Kleopa et al [12] who found that there was a larger survival benefit in those with bulbar onset MND after initiation of NIV as well as other studies with similar findings [29].

This study also found that those with bulbar onset MND have more marked impairment in PFT measurements at diagnosis compared to those with limb onset MND, with SNIP and PCF values being statistically significant lower in those with bulbar onset MND. This highlights a worse overall prognosis of bulbar onset MND when compared with limb onset MND. It has long been established that the rate of decline of respiratory function is related to mortality. We have shown in this study that the SNIP and PCF values declined significantly between diagnosis and values recorded within 6 months of death. SNIP measurements can better predict respiratory muscle function as they linearly decline with disease progression, can be better performed in advanced disease and are a reliable predictor of mortality and can better indicate earlier respiratory muscle dysfunction than FVC [24-28]. Figure 2 highlights the gradual decline of SNIP and PCF in the year before death of all patients for which this data was available.
It could be concluded from this that serial SNIP and PCF measurements, as is carried out in our centre, are an accurate measure of respiratory muscle decline and can help predict mortality.

There is a lack of data regarding the best location for NIV set up for MND patients. As mentioned, our institute aims to set up NIV while the patient is in hospital so that nursing and physiotherapy staff can help with mask adjustment and therefore improve compliance.

Although 70% of the patients for which this data was available had their NIV set up while in hospital compliance amongst this group was lower compared with those set up at home. There may be several reasons for this including that those who are able to be set up at home may have less severe phenotypes and/or may be more willing to embrace the intervention. More research is required in this area, but it is a unique data point to our current study.

**Advantages and Limitations**

One of the limitations of this study was that it was a retrospective study performed over a 5-year period and therefore it was not possible to standardise data collection of each patient. Practise in the clinic changed significantly during this time which influenced the data available. As the clinic became established a physiotherapist, speech and language therapist, neurology consultant and respiratory consultant saw the patient on every visit. This meant that compliance data was analysed and recorded and that the physiotherapist performed spirometry and recorded SNIP and PCF values at every visit. This was not always the case with earlier clinics which resulted in a lack of PFT data for certain patients. Secondly, in some cases there was missing data especially elements of PFTs. This was due to a combination of factors including lack of availability in the PFT lab, patient difficulty travelling to appointments and patient difficulty carrying out the test. This affected our ability to accurately measure FVC decline over time. A further limitation is that not every patient was set up in NIV in our institute. A subset of patients were set up at other institutes prior to assessment at our institution. This resulted in difficulties retrieving compliance data for some patients. This was particularly the case in earlier clinics, but this issue was subsequently resolved by standardising practice with one primary vendor within the region. Given its observational nature, our study while showing robust associations cannot establish causation, and a variety of factors may have contributed to the observed difference in survival.

One of the main advantages of this study includes the large sample size of 111 patients. This sample is representative of MND patients from all over the south of Ireland. Furthermore, we believe that this is the first study of its kind in an Irish MND population. Another advantage was that there was a high uptake of NIV among our patient cohort with two-thirds of patients who continued to use NIV using it optimally. Finally, we analysed home and inpatient set up in our patient cohort and looked at how this affected compliance which is a factor rarely mentioned in other studies.

**Conclusion**

This is a retrospective chart analysis of 111 patients who attended a multidisciplinary MND clinic at our institute over a 5-year period. We collected data on NIV usage and compliance as well as PFT results. It
was found that there is a statistically significant advantage to using NIV optimally and this was also seen in those with bulbar onset MND who were compliant with NIV compared to those who did not use NIV.

**Abbreviations**

FVC – forced vital capacity

MND – motor neuron disease

NIV – non-invasive ventilation

PCF – peak cough flow

PEG – percutaneous endoscopic gastrostomy

PFTs – pulmonary function tests

SD – standard deviation

SNIP – sniff nasal inspiratory pressure

**Declarations**

- Ethics approval and consent to participate: Ethical approval was granted by the Cork Research Ethics Committee
- Consent for publication: Not applicable
- Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
- Competing interests: The authors declare that they have no competing interests.
- Funding: None
- Authors’ contributions: LJW collected data from charts, analysed data and wrote article. KFD analysed data. FG was involved in editing the paper. EOS was involved in data collection. JE assisted with statistics and editing of the paper. AMR was involved in data collection and paper editing. DMM developed the concept for the study, was involved in data collection and was the primary editor of the paper.
- Acknowledgements: Not applicable.

**References**

1. Caroscio JT, Mulvihill MN, Sterling R, Abrams B. Amyotrophic lateral sclerosis: its natural history. Neurol Clin. 1987;5(1):1–8.
2. Munsat TL, Andres PL, Finison L, Conlon T, Thibodeau L. The natural history of motor neuron loss in amyotrophic lateral sclerosis. Neurology. 1988;38:409–13.

3. Ringel SP, Murphy JR, Alderson MK. The natural history of amyotrophic lateral sclerosis. Neurology. 1993;43:1316–22.

4. Braun SR. Respiratory system in amyotrophic lateral sclerosis. Neurol Clin. 1987;5(1):9–31.

5. O’Neill CL, Williams TL, Peel ET, McDermott CJ, Shaw PJ, Gibson GJ, Bourke SC. Non-invasive ventilation in motor neuron disease: an update of current UK practice. J Neurol Neurosurg Psychiatry. 2012;83:371e376.

6. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forsheaw D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218–26.

7. Bourke SC, Bullock RE, Williams TL, Shaw PJ, Gibson GJ. Non-invasive ventilation in ALS: indications and effect on quality of life. Neurology. 2003;61(2):171–7.

8. Hardiman O. Symptomatic treatment of respiratory and nutritional failure in amyotrophic lateral sclerosis. J Neurol. 2000;247:245–51.

9. Lyall RA, Donaldson N, Fleming T, Wood C, Newsom-Davies I, Polkey MI, et al. A prospective study of quality of life in ALS patients treated with non-invasive ventilation. Neurology. 2001;57:153–6.

10. Tandan R, Bradley WG. Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management. Ann Neurol. 1985;18:271–80.

11. Vitacca M, Montini A, Lunetta C, Banfi P, Bertella E, De Mattia E, et al. Impact of an early respiratory care programme with non-invasive ventilation adaptation in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2018;25(3):556-e533.

12. Kleopa KA, Sherman M, Neal B, Ramano GJ, Heiman-Patterson T. Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci. 1999;164:82 – 88.

13. Sherman MS, Paz HL. Review of respiratory care of the patient with lateral sclerosis. Respiration. 1994;61(2):61–7.

14. Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luis ML. Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci. 1995;129:19–26.

15. Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H. Effect of non-invasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Int Med. 1997;127(6):450–3.

16. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5(2):140–7.

17. Piepers S, van den Berg JP, Kalmijn S. van der Pol WL, Wokke JH, Lindeman E, van den Berg LH. Effect of non-invasive ventilation on survival, quality of life, respiratory function and cognition: a
review of the literature. Amyotroph Lateral Scler 2006;7: 195–200.

18. Carey Z, Gottfried SB, Levy R. Ventilatory muscle support in respiratory failure with nasal positive pressure ventilation. Chest. 1990;97:150–8.

19. Heckmatt JZ, Loh L, Dubowitz V. Night-time ventilation in neuromuscular diseases. Lancet. 1990;335:579–82.

20. Meduri GN, Shala NA, Fox RC, Jones CB, Leeper KY, Wunderink RG. Non-invasive face mask mechanical ventilation in patients with acute respiratory failure. Chest. 1991;100:445–54.

21. Pinto A, de Carvalho M, Evangelista T, Lopes T, Sales-Luís A. L. Nocturnal pulse oximetry: a new approach to establish the appropriate time for non-invasive ventilation in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:31–5.

22. Lechtzin N, Scott Y, Busse AM, Clawson LL, Kimball R, Wiener CM. Early use of non-invasive ventilation prolongs survival in subjects with ALS. Amyotroph Lateral Scler. 2007;8:185–8.

23. Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77(3):390–2.

24. Morgan RK, McNally S, Alexander M, Conroy R, Hardiman O, Costello RW. Use of Sniff Nasal-Inspiratory Force to Predict Survival in Amyotrophic Lateral Sclerosis. Am J Respir Crit Care. 2005;171:269–74.

25. Polkey MI, Lyall RA, Yang K, Johnson E, Leigh PN, Moxham J. Respiratory Muscle Strength as a Predictive Biomarker for Survival in Amyotrophic Lateral Sclerosis. Am J Respir Crit Care Med. 2017;195:86–95.

26. Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347:1425–31.

27. Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain. 2001;124:2000–13.

28. Capozzo R, Quaranta VN, Pellegrini F, Fontana A, Copetti M, Carratù P, Panza F, et al. Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis. J Neurol. 2015;262(3):593–60.

29. Panchabhai TS, Mireles Cabodevilla E, Pioro EP, Wang X, Han Z, Aboussouan LS. Pattern of lung function decline in patients with amyotrophic lateral sclerosis: implications for timing of non-invasive ventilation. ERJ Open Res. 2019;5:00044–2019.

30. Berlowitz DJ, Howard ME, Fiore JF Jr, Vander Hoorn S, O'Donoghue FJ, Westlake J, et al. Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort. J Neurol Neurosurg Psychiatry. 2016;87:280–6.

31. Walsh LJ, Murphy DM. The benefit of non-invasive ventilation in Motor Neuron Disease. Open Respir Med 2020 Dec 15; 14:53–61.

32. Aboussouan LS, Khan SU, Banerjee M, Arroliga AC, Mitsumoto H. Objective measures of the efficacy of non-invasive positive-pressure ventilation in amyotrophic lateral sclerosis. Muscle Nerve.
Survival curves. A - compares overall survival for those with limb onset disease versus those with bulbar onset disease with a statistically significant longer survival seen in those with limb onset MND, p=0.01. B - compares optimal NIV use i.e. 70% usage for greater than 4 hours per day. Those who used NIV optimally survival statistically significant longer, 26 months than those who did use NIV at all at 12 months, p=0.021. C - this survival curve looks at optimal use of NIV versus no NIV in those with bulbar onset NIV and finds that there is a statistically significant longer survival in those who optimally use NIV.
(23 months) versus those who do not use NIV at all (8 months, p=0.001) in bulbar onset disease. D – is similar to graph C but compares optimal use of NIV to no NIV in those with limb onset disease and finds that there is no statistically significant survival advantage (33 months v 22 months, p=0.824).

**Figure 2**

Decline in SNIP and PCF values 3, 6, 9 and 12 months prior to death. This data was available on n=61 patients in this study. In the year prior to death, there was a gradual decline in SNIP and PCF in the majority of patients.